Growth hormone therapy in children and adolescents: pharmacokinetic/pharmacodynamic considerations and emerging indications

Bibliography

• Hardin DS, Woo J, Butsch R, et al. Current prescribing practices and opinions about growth hormone therapy: results of a nationwide survey of paediatric endocrinologists. Clin Endocrinol (Oxf) 2007;66:85-94
   PubMed Web of Science ®Google Scholar
• Drake WM, Howell SJ, Monson JP, et al. Optimizing gh therapy in adults and children. Endocr Rev 2001;22:425-50
   PubMed Web of Science ®Google Scholar
• Hardin DS, Kemp SF, Allen DB. Twenty years of recombinant human growth hormone in children: relevance to pediatric care providers. Clin Pediatr (Phila) 2007;46:279-86
   PubMed Web of Science ®Google Scholar
• Reiter EO, Price DA, Wilton P, et al. Effect of growth hormone (GH) treatment on the near-final height of 1258 patients with idiopathic GH deficiency: analysis of a large international database. J Clin Endocrinol Metab 2006;91:2047-54
   PubMed Web of Science ®Google Scholar
• Wilson TA, Rose SR, Cohen P, et al. Update of guidelines for the use of growth hormone in children: the Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee. J Pediatr 2003;143:415-21
   PubMed Web of Science ®Google Scholar
• Lee MM. Clinical practice. Idiopathic short stature. N Engl J Med 2006;354:2576-82
   PubMed Web of Science ®Google Scholar
• Darendeliler F, Karagiannis G, Wilton P. Headache, idiopathic intracranial hypertension and slipped capital femoral epiphysis during growth hormone treatment: a safety update from the KIGS database. Horm Res 2007;68(Suppl 5):41-7
   PubMedGoogle Scholar
• Carlsson LM, Rosberg S, Vitangcol RV, et al. Analysis of 24-hour plasma profiles of growth hormone (GH)-binding protein, GH/GH-binding protein-complex, and GH in healthy children. J Clin Endocrinol Metab 1993;77:356-61
   PubMed Web of Science ®Google Scholar
• Zadik Z, Chalew SA, Kowarski A. The definition of a spontaneous growth hormone (GH) peak: studies in normally growing and GH-deficient children. J Clin Endocrinol Metab 1992;74:801-5
   PubMed Web of Science ®Google Scholar
• Reiter EO, Attie KM, Moshang T Jr, et al. A multicenter study of the efficacy and safety of sustained release GH in the treatment of naive pediatric patients with GH deficiency. J Clin Endocrinol Metab 2001;86:4700-6
   PubMed Web of Science ®Google Scholar
• Clemmons DR. Long-acting forms of growth hormone-releasing hormone and growth hormone: effects in normal volunteers and adults with growth hormone deficiency. Horm Res 2007;68(Suppl 5):178-81
   PubMedGoogle Scholar
• Sun YN, Lee HJ, Almon RR, et al. A pharmacokinetic/pharmacodynamic model for recombinant human growth hormone effects on induction of insulin-like growth factor I in monkeys. J Pharmacol Exp Ther 1999;289:1523-32
   PubMed Web of Science ®Google Scholar
• Keller A, Wu Z, Kratzsch J, et al. Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administration. Eur J Endocrinol 2007;156:647-53
   PubMed Web of Science ®Google Scholar
• Kemp SF, Fielder PJ, Attie KM, et al. Pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient children. J Clin Endocrinol Metab 2004;89:3234-40
   PubMed Web of Science ®Google Scholar
• Chalew SA, Phillip M, Kowarski AA. Plasma integrated concentration of growth hormone after recombinant human growth hormone injection. Implications for determining an optimal dose. Am J Dis Child 1993;147:274-8
   PubMedGoogle Scholar
• Dahlgren J. Easypod: a new electronic injection device for growth hormone Expert Rev Med Devices 2008;5:297-304
   PubMed Web of Science ®Google Scholar
• Dorr HG, Zabransky S, Keller E, et al. Are needle-free injections a useful alternative for growth hormone therapy in children? Safety and pharmacokinetics of growth hormone delivered by a new needle-free injection device compared to a fine gauge needle. J Pediatr Endocrinol Metab 2003;16:383-92
   PubMed Web of Science ®Google Scholar
• Agerso H, Moller-Pedersen J, Cappi S, et al. Pharmacokinetics and pharmacodynamics of a new formulation of recombinant human growth hormone administered by ZomaJet 2 Vision, a new needle-free device, compared to subcutaneous administration using a conventional syringe. J Clin Pharmacol 2002;42:1262-8
   PubMed Web of Science ®Google Scholar
• Brearley C, Priestley A, Leighton-Scott J, et al. Pharmacokinetics of recombinant human growth hormone administered by cool.click 2, a new needle-free device, compared with subcutaneous administration using a conventional syringe and needle. BMC Clin Pharmacol 2007;7:10
   PubMedGoogle Scholar
• Houdijk EC, Herdes E, Delemarre-Van de Waal HA. Pharmacokinetics and pharmacodynamics of recombinant human growth hormone by subcutaneous jet- or needle-injection in patients with growth hormone deficiency. Acta Paediatr 1997;86:1301-7
   PubMed Web of Science ®Google Scholar
• Catalina PF, Paramo C, Andrade MA, et al. Growth hormone distribution kinetics are markedly reduced in adults with growth hormone deficiency. Clin Endocrinol (Oxf) 2007;66:341-7
   PubMed Web of Science ®Google Scholar
• Schaefer F, Baumann G, Haffner D, et al. Multifactorial control of the elimination kinetics of unbound (free) growth hormone (GH) in the human: regulation by age, adiposity, renal function, and steady state concentrations of GH in plasma. J Clin Endocrinol Metab 1996;81:22-31
   PubMed Web of Science ®Google Scholar
• Hansen TK, Gravholt CH, Orskov H, et al. Dose dependency of the pharmacokinetics and acute lipolytic actions of growth hormone. J Clin Endocrinol Metab 2002;87:4691-8
   PubMed Web of Science ®Google Scholar
• Cohen P, Rogol AD, Howard CP, et al. Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study. J Clin Endocrinol Metab 2007;92:2480-6
   PubMed Web of Science ®Google Scholar
• Vahl N, Moller N, Lauritzen T, et al. Metabolic effects and pharmacokinetics of a growth hormone pulse in healthy adults: relation to age, sex, and body composition. J Clin Endocrinol Metab 1997;82:3612-8
   PubMed Web of Science ®Google Scholar
• Beentjes JA, Kerstens MN, Dullaart RP. Effects of growth hormone replacement on cortisol metabolism in hypopituitary patients treated with cortisone acetate. Scand J Clin Lab Invest 2001;61:277-86
   PubMed Web of Science ®Google Scholar
• Swords FM, Carroll PV, Kisalu J, et al. The effects of growth hormone deficiency and replacement on glucocorticoid exposure in hypopituitary patients on cortisone acetate and hydrocortisone replacement. Clin Endocrinol (Oxf) 2003;59:613-20
   PubMed Web of Science ®Google Scholar
• Dhir RN, Dworakowski W, Thangavel C, et al. Sexually dimorphic regulation of hepatic isoforms of human cytochrome p450 by growth hormone. J Pharmacol Exp Ther 2006;316:87-94
   PubMed Web of Science ®Google Scholar
• Land C, Blum WF, Shavrikova E, et al. Predicting the growth response to growth hormone (GH) treatment in prepubertal and pubertal children with isolated GH deficiency – model validation in an observational setting (GeNeSIS). J Pediatr Endocrinol Metab 2007;20:685-93
   PubMed Web of Science ®Google Scholar
• Ranke MB, Lindberg A, Martin DD, et al. The mathematical model for total pubertal growth in idiopathic growth hormone (GH) deficiency suggests a moderate role of GH dose. J Clin Endocrinol Metab 2003;88:4748-53
   PubMed Web of Science ®Google Scholar
• Dahlgren J, Kristrom B, Niklasson A, et al. Models predicting the growth response to growth hormone treatment in short children independent of GH status, birth size and gestational age. BMC Med Inform Decis Mak 2007;7:40
   PubMedGoogle Scholar
• Bakker B, Frane J, Anhalt H, et al. Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children. J Clin Endocrinol Metab 2008;93:352-7
   PubMed Web of Science ®Google Scholar
• Baumann G. Growth hormone binding protein 2001. J Pediatr Endocrinol Metab 2001;14:355-75
   PubMed Web of Science ®Google Scholar
• Fisker S. Physiology and pathophysiology of growth hormone-binding protein: methodological and clinical aspects. Growth Horm IGF Res 2006;16:1-28
   PubMed Web of Science ®Google Scholar
• Zhang Y, Jiang J, Black RA, et al. Tumor necrosis factor-alpha converting enzyme (TACE) is a growth hormone binding protein (GHBP) sheddase: the metalloprotease TACE/ADAM-17 is critical for (PMA-induced) GH receptor proteolysis and GHBP generation. Endocrinology 2000;141:4342-8
   PubMed Web of Science ®Google Scholar
• O'Leary MJ, Quinton N, Ferguson CN, et al. In rats with sepsis, the acute fall in IGF-I is associated with an increase in circulating growth hormone-binding protein levels. Intensive Care Med 2000;26:1547-52
   PubMed Web of Science ®Google Scholar
• Van den Berghe G, Baxter RC, Weekers F, et al. A paradoxical gender dissociation within the growth hormone/insulin-like growth factor I axis during protracted critical illness. J Clin Endocrinol Metab 2000;85:183-92
   PubMed Web of Science ®Google Scholar
• Wang X, Jiang J, Warram J, et al. Endotoxin-induced proteolytic reduction in hepatic growth hormone (GH) receptor: a novel mechanism for GH insensitivity. Mol Endocrinol 2008;22:1427-37
   PubMed Web of Science ®Google Scholar
• Veldhuis JD, Johnson ML, Faunt LM, et al. Influence of the high-affinity growth hormone (GH)-binding protein on plasma profiles of free and bound GH and on the apparent half-life of GH. Modeling analysis and clinical applications. J Clin Invest 1993;91:629-41
   PubMed Web of Science ®Google Scholar
• Mannor DA, Winer LM, Shaw MA, et al. Plasma growth hormone (GH)-binding proteins: effect on GH binding to receptors and GH action. J Clin Endocrinol Metab 1991;73:30-4
   PubMed Web of Science ®Google Scholar
• Clark RG, Mortensen DL, Carlsson LM, et al. Recombinant human growth hormone (GH)-binding protein enhances the growth-promoting activity of human GH in the rat. Endocrinology 1996;137:4308-15
   PubMed Web of Science ®Google Scholar
• Maes M, Maiter D, Massa G, et al. Growth hormone receptor and binding protein: roles in cellular responsiveness to growth hormone. Ann Endocrinol (Paris) 1995;56:253-8
   PubMed Web of Science ®Google Scholar
• Turyn D, Dominici FP, Sotelo AI, et al. Growth hormone-binding protein enhances growth hormone activity in vivo. Am J Physiol 1997;273:E549-56
   PubMed Web of Science ®Google Scholar
• Tzanela M, Wagner C, Tannenbaum GS. Recombinant human growth hormone-binding protein fails to enhance the in vivo bioactivity of human growth hormone in normal rats. Endocrinology 1997;138:5316-24
   PubMed Web of Science ®Google Scholar
• Hansen TK, Fisker S, Hansen B, et al. Impact of GHBP interference on estimates of GH and GH pharmacokinetics. Clin Endocrinol (Oxf) 2002;57:779-86
   PubMed Web of Science ®Google Scholar
• Higham CE, Jostel A, Trainer PJ. IGF-I measurements in the monitoring of GH therapy. Pituitary 2007;10:159-63
   PubMed Web of Science ®Google Scholar
• Frasier SD, Costin G, Lippe BM, et al. A dose-response curve for human growth hormone. J Clin Endocrinol Metab 1981;53:1213-7
   PubMed Web of Science ®Google Scholar
• Park P, Cohen P. Insulin-like growth factor I (IGF-I) measurements in growth hormone (GH) therapy of idiopathic short stature (ISS). Growth Horm IGF Res 2005;15(Suppl A):S13-20
   PubMed Web of Science ®Google Scholar
• Ranke MB, Traunecker R, Martin DD, et al. IGF-I and IGF binding protein-3 levels during initial GH dosage step-up are indicators of GH sensitivity in GH-deficient children and short children born small for gestational age. Horm Res 2005;64:68-76
   PubMed Web of Science ®Google Scholar
• Slonim AE, Bulone L, Damore MB, et al. A preliminary study of growth hormone therapy for Crohn's disease. N Engl J Med 2000;342:1633-7
   PubMed Web of Science ®Google Scholar
• Mauras N, George D, Evans J, et al. Growth hormone has anabolic effects in glucocorticosteroid-dependent children with inflammatory bowel disease: a pilot study. Metabolism 2002;51:127-35
   PubMed Web of Science ®Google Scholar
• Denson L, Bezold R, Moyer S, et al. A randomized trial of growth hormone (GH) in active pediatric crohn's disease (CD). J Pediatr Gastroenterol Nutr 2007;45:E77
   Google Scholar
• Hardin DS, Ellis KJ, Dyson M, et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. J Pediatr 2001;139:636-42
   PubMed Web of Science ®Google Scholar
• Schnabel D, Grasemann C, Staab D, et al. A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics 2007;119:e1230-8
   PubMed Web of Science ®Google Scholar
• Simon D, Prieur AM, Quartier P, et al. Early recombinant human growth hormone treatment in glucocorticoid-treated children with juvenile idiopathic arthritis: a 3-year randomized study. J Clin Endocrinol Metab 2007;92:2567-73
   PubMed Web of Science ®Google Scholar
• Walters T, Gilman A, Griffiths A. Linear growth improves during infliximab therapy in children with chronically active severe Crohn disease. Inflamm Bowel Dis 2007; In press
   PubMedGoogle Scholar